Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Patrick C. Hines, MD, PhD
Researcher Assistant Professor in the Department of Physiology
Wayne State University School of Medicine
3901 Beaubien Street
Pediatrics Critical Care, Medicine
Detroit, Michigan, United States
Patrick C. Hines, MD, PhD is an experienced pediatric critical care physician (general and cardiac) and a vascular biology research scientist. He is also the Founder and CEO of Functional Fluidics, a startup company developing clinical bioassays to measure blood function during simulated flow with microliters of whole blood. This technology is being adopted by pharmaceutical companies, clinicians, and research scientists to evaluate new therapies for red blood cell disorders such as sickle cell disease, coagulation disorders, and cancer. Dr. Hines was selected to the inaugural class of the Aspen Global Leadership Network’s Health Innovators Fellowship. He was the Chairman of the board of directors for the SNMA in the past. Areas of Interest: Role of beta-adrenergic stimulation in erythrocyte adhesion to the pulmonary vasculature; mechanisms of sickle erythrocyte adhesion
Representative Publications:
Central nervous system events in children with sickle cell disease presenting acutely with headache
Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion
+myBinderRelated Content
-
John T. Horan MD, MPHJohn T. Horan, MD, MPH, is Associate Pro...
-
William Owen, MDDr. William Owen is a pediatric hematolo...
-
Family functioning, medical self-management, and health outcomes among school-aged children with sickle cell disease...BACKGROUND: Informed by the Pediatric S...
-
Four Solutions for Sickle Cell Disease SupportWhen Precious Lee was a year old, she be...
-
The Sickle Cell Infusion Center at Johns HopkinsThe Sickle Cell Center for Adults is ded...
-
Citizens for Quality Sickle Cell CareThe New England Sickle Cell Institute at...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
